Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Autor: Seda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, Sema Sezgin Goksu, Akin Ozturk, Zehra Sucuoglu Isleyen, Jamshid Hamdard, Sedat Yildirim, Tolga Dogan, Selver Isik, Abdussamet Celebi, Burcu Belen Gulbagci, Nail Paksoy, Mutlu Dogan, Haci Mehmet Turk, Ahmet Bilici, Ali Murat Tatli, Sinem Akbas, Nedim Turan, Ilhan Hacibekiroglu, Gamze Gokoz Dogu, Adnan Aydiner, Ahmet Taner Sumbul, Serap Akyurek, Merih Yalciner, Ahmet Demirkazik, Pinar Gursoy, Musa Baris Aykan, Elif Sahin, İbrahim Karadag, Osman Kostek, Muhammed Muhiddin Er, Mehmet Artaç, Yakup Duzkopru, Dincer Aydin, Deniz Isik, Yusuf Karakas, Saadettin Kilickap, Cihan Erol, Bilgin Demir, Burak Civelek, Yakup Ergun, Muhammed Bulent Akinci, Izzet Dogan, Nuri Karadurmus, Perran Fulden Yumuk, Mehmet Ali Nahit Sendur

Publikováno v: Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)

Abstract Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brai

Externí odkaz: https://doaj.org/article/dfd4fc84465f4b4985707fa241e217b7

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Autor: Zsolt Markóczy, Veronika Sárosi, Iveta Kudaba, Gabriella Gálffy, Ülkü Yilmaz Turay, Ahmet Demirkazik, Gunta Purkalne, Attila Somfay, Zsolt Pápai-Székely, Erzsébet Rásó, Gyula Ostoros

Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)

Abstract Background Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated in routine clinical

Externí odkaz: https://doaj.org/article/d7176d935e0a4a359302b37df3fb11e5

Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group

Autor: Mustafa Gürbüz, Saadettin Kiliçkap, Ahmet Bilici, Nuri Karadurmuş, Ahmet Sezer, Mehmet Ali Nahit Şendur, Semra Paydaş, Mehmet Artaç, Perran Fulden Yumuk, Pinar Gürsoy, Mükremin Uysal, Hasan Şenol Coşkun, Ali Murat Tatli, Fatih Selçukbiricik, Umut Dişel, Elif Berna Köksoy, Deniz Can Güven, Muzaffer Uğrakli, Erman Akkuş, Şebnem Yücel, Cihan Erol, Serdar Karakaya, Teoman Şakalar, Nijat Khanmammadov, Nail Paksoy, Ahmet Demirkazik

Publikováno v: Medicine. 101(50)

Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fa05044789f228338ef3c9ada33cec1
https://pubmed.ncbi.nlm.nih.gov/36550824

Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Autor: Sadettin Kilickap, Mutlu Hizal, Ahmet Gulmez, Okan Avci, Burak Yasin Aktas, Havva Yesil Cinkir, Emir Celik, Mustafa Gürbüz, Berna Oksuzoglu, Ali Murat Tatli, Gulhan Ipek Deniz, Cihan Erol, Erdem Sen, Fulden Yumuk, A İlhan, Şebnem Yücel, Semra Paydas, Ozkan Alan, Engin Kut, Fatih Karatas, Atakan Demir, Murat Ayhan, Bulent Yalcin, Halil Taskaynatan, Tugba Basoglu, Serkan Menevse, Deniz Tataroğlu Özyükseler, Nadiye Akdeniz, Sinan Koca, Mustafa Karaagac, Burak Bilgin, Didem Sener Dede, Mehmet Ali Nahit Sendur, Muhammed Bulent Akinci, Izzet Dogan, Ahmet Demirkazik, Teoman Sakalar

Publikováno v: Journal of Cancer Research and Clinical Oncology. 147:2145-2152

The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that invest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d89c7618b60463a480bb0c32d1d2ee
https://doi.org/10.1007/s00432-020-03501-6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)

Autor: Jonathan W Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Każarnowicz, György Losonczy, Nikolay V Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares, Nataliia Voitko, Andrzej Kazarnowicz, Mustafa Özgüroglu, Nikolay Conev, Maximilian Hochmair, Otto Burghuber, Irfan Çiçin, Vladimir Moiseenko, Mustafa Erman, Dariusz Kowalski, Marek Wojtukiewicz, Hryhoriy Adamchuk, Alexander Vasilyev, Serhii Shevnia, Spartak Valev, Maria Amelia Insa Molla, Grygorii Ursol, Anne Chiang, Sylvia Hartl, Zsolt Horváth, Gábor Pajkos, Sang-We Kim, Alexey Smolin, Tuncay Göksel, Shaker Dakhil, Jaromir Roubec, Krisztina Bogos, Robin Cornelissen, Jong-Seok Lee, Maria Rosario Garcia Campelo, Marta Lopez Brea, Ahmet Alacacioglu, Ignacio Casarini, Rumyana Ilieva, Ivan Tonev, Attila Somfay, Jair Bar, Alona Zer Kuch, Mauro Minelli, Roberta Bartolucci, Fausto Roila, Haruhiro Saito, Koichi Azuma, Gyeong-Won Lee, Alexander Luft, Michal Urda, Juan Ignacio Delgado Mingorance, Margarita Majem Tarruella, David Spigel, Krassimir Koynov, Milada Zemanova, Jens Panse, Christian Schulz, Zsolt Pápai Székely, Veronika Sárosi, Angelo Delmonte, Anna Cecilia Bettini, Makoto Nishio, Isamu Okamoto, Lizza Hendriks, Slawomir Mandziuk, Yun Gyoo Lee, Lyubov Vladimirova, Dolores Isla Casado, Manuel Domine Gomez, Alejandro Navarro Mendivil, Teresa Morán Bueno, Shang-Yin Wu, Jeanna Knoble, Jana Skrickova, Violetka Venkova, Werner Hilgers, Eckart Laack, Helge Bischoff, Andrea Fülöp, Ibolya Laczó, Judit Kósa, András Telekes, Tatsuya Yoshida, Shintaro Kanda, Toyoaki Hida, Hidetoshi Hayashi, Tadashi Maeda, Tetsuji Kawamura, Yasuharu Nakahara, Niels Claessens, Ki Hyeong Lee, Chao-Hua Chiu, Sheng-Hao Lin, Chien-Te Li, Ahmet Demirkazik, Eric Schaefer, Petros Nikolinakos, Jeffrey Schneider, Sunil Babu, Bernd Lamprecht, Michael Studnicka, Carlos Fausto Nino Gorini, Juraj Kultan, Vitezslav Kolek, Pierre-Jean Souquet, Denis Moro-Sibilot, Maya Gottfried, Egbert Smit, Kyung Hee Lee, Peter Kasan, Jozef Chovanec, Olexandr Goloborodko, Oleksii Kolesnik, Yuriy Ostapenko, Shailendra Lakhanpal, Basir Haque, Winston Chua, Joseph Stilwill, Susana Noemi Sena, Gustavo Colagiovanni Girotto, Pedro Rafael Martins De Marchi, Fabricio Augusto Martinelli de Oliveira, Pedro Dos Reis, Rositsa Krasteva, Yanqiu Zhao, Chengshui Chen, Leona Koubkova, Gilles Robinet, Christos Chouaid, Christian Grohe, Jürgen Alt, Eszter Csánky, Éva Somogyiné Ezer, Norman Isaac Heching, Young Hak Kim, Shinji Aatagi, Shoichi Kuyama, Daijiro Harada, Naoyuki Nogami, Hiroshi Nokihara, Hisatsugu Goto, Agnes Staal van den Brekel, Eun Kyung Cho, Joo-Hang Kim, Doina Ganea, Tudor Ciuleanu, Ekaterina Popova, Dina Sakaeva, Marian Stresko, Pavol Demo, Robert Godal, Yu-Feng Wei, Yen-Hsun Chen, Te-Chun Hsia, Kang-Yun Lee, Huang-Chih Chang, Chin-Chou Wang, Afshin Dowlati, Christopher Sumey, Steven Powell, Jonathan Goldman, Juan Jose Zarba, Emilio Batagelj, Andrea Viviana Pastor, Mauro Zukin, Clarissa Serodio da Rocha Baldotto, Luis Alberto Schlittler, Aknar Calabrich, Claudia Sette, Asen Dudov, Caicun Zhou, Hervé Lena, Susanne Lang, Zsuzsanna Pápai, Koichi Goto, Shigeki Umemura, Kenya Kanazawa, Yu Hara, Masahiro Shinoda, Masahiro Morise, Jeroen Hiltermann, Robert Mróz, Andrei Ungureanu, Igor Andrasina, Gee-Chen Chang, Ihor Vynnychenko, Yaroslav Shparyk, Anna Kryzhanivska, Helen Ross, Kailhong Mi, Rodney Jamil, Michael Williamson, Joseph Spahr, Zhigang Han, Mengzhao Wang, Zhixiong Yang, Jie Hu, Wei Li, Jun Zhao, Jifeng Feng, Shenglin Ma, Xiangdong Zhou, Zongan Liang, Yi Hu, Yuan Chen, Minghong Bi, Yongqian Shu, Kejun Nan, Jianying Zhou, Wei Zhang, Rui Ma, Nong Yang, Zhong Lin, Gang Wu, Jian Fang, Helong Zhang, Kai Wang, Zhendong Chen

Publikováno v: The Lancet Oncology, 22(1), 51-65. Lancet Publishing Group

Background: First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus platinum–etoposide alone in patients with extensive-stage small-cell lung cance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebbedf402a20a646763dade225df0a3b
https://doi.org/10.1016/S1470-2045(20)30539-8